In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.
about
Neurofunctional imaging of β-cell dynamicsApplications of in vivo imaging in the evaluation of the pathophysiology of viral and bacterial infections and in development of countermeasures to BSL3/4 pathogensImaging pancreatic islet cells by positron emission tomographyData-driven event-by-event respiratory motion correction using TOF PET list-mode centroid of distribution.A Synthetic Heterobivalent Ligand Composed of Glucagon-Like Peptide 1 and Yohimbine Specifically Targets β Cells Within the PancreasCross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes.Vesicular monoamine transporter, type 2 (VMAT2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas.Strategies for clinical trials in type 1 diabetesDeletion of β-Arrestin2 in mice limited pancreatic beta-cell expansion under metabolic stress through activation of JNK pathway.List-mode reconstruction for the Biograph mCT with physics modeling and event-by-event motion correction.Whole organ and islet of Langerhans dosimetry for calculation of absorbed doses resulting from imaging with radiolabeled exendinLocalization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease.Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of 18F-FP-DTBZ in baboonsSpecies-specific vesicular monoamine transporter 2 (VMAT2) expression in mammalian pancreatic beta cells: implications for optimising radioligand-based human beta cell mass (BCM) imaging in animal models.Targets and probes for non-invasive imaging of β-cells.Beta-cell imaging: call for evidence-based and scientific approach.Imaging beta-cell mass and function in situ and in vivo.Pancreatic β-cell imaging in humans: fiction or option?Pancreas-Specific Delivery of β-Cell Proliferating Small Molecules.Failed PET Application Attempts in the Past, Can We Avoid Them in the Future?In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use.GPR44 is a pancreatic protein restricted to the human beta cell.Inside the pancreas: progress and challenges of human beta cell mass quantification.Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis.PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [¹⁸F]FP-DTBZ in baboons.Event-by-event respiratory motion correction for PET with 3D internal-1D external motion correlation.β-Cell mass imaging with DTBZ positron emission tomography: is it possible?Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-PHNO.CD99 as surface anchor for human islet endocrine cell purification.Respiratory Motion Compensation for PET/CT with Motion Information Derived from Matched Attenuation Corrected Gated PET Data.Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic miceTranslational Molecular Imaging of Diabetes
P2860
Q26829645-D09BF7B5-23BD-49BD-BB71-00436A1DB77CQ26852810-A7A59E71-8359-4563-93EF-6060080FF114Q28075496-BD8E1E43-C544-485D-89FE-26BD3FC9CE7BQ36375438-46F2E71D-8DBA-4342-868F-E6C1C84C124DQ36395175-710139B7-AF37-4031-B17A-5186FA1CFBD9Q36665699-10A31F39-FD7F-472E-8050-485E4AA195B9Q36707357-6138760A-1939-46CD-ABD2-0B0F93DB473DQ36995370-5172B948-D88B-41D2-AD23-1619ED72CC50Q37218931-0EE66AD2-3F9A-4399-8B69-F5997790AB02Q37330368-B737C2C6-A9F7-4D9F-9F7E-CB075422DD91Q37571152-3174EBE3-13FC-4F19-A5D1-1E7EDED146D2Q37591449-0F0DA344-DDC9-4137-B5A5-E5C6173B0997Q37596164-3B2BF643-3F8B-4B94-A157-A50EE5CD7927Q37640085-9ACF1513-F7ED-4CDA-80E9-A622A4FAEF4EQ37662672-F1FCE6C1-319C-4FFA-855A-89967B0B06D3Q38081852-E6B46C5C-9156-48B8-9CC4-44D0729126AFQ38108757-74BDC1CA-3346-4D84-978D-AD424CA64FB4Q38558006-DEEBDBEE-59E7-4488-9062-DCCC9DF126DAQ38776961-614F38B8-8716-40CA-85F3-F89245D1A7D7Q38800009-0814F618-3325-4ABB-BAF3-F6BCD1F09BE0Q38812324-B9C88DDC-A7CF-41F7-BA5A-6EC6125E5D67Q38827901-6A1F240B-E09D-4A46-AC41-FF20F0B7637FQ39238015-DBD96725-34F7-4120-8AE7-6F9161D3E167Q41689680-0159AF8C-E9C6-4561-913A-6C2C371CFCBFQ42149421-16FE7C1F-5242-4FBE-AF9D-17A4C1698B48Q45929721-307055E2-7A4B-4FA7-ABFB-6B485BB73BD2Q46145676-606C0828-A9AD-483F-82D6-F4A58586254BQ47839163-C141FEFA-007D-41A0-B3B1-AD0966292E55Q48328426-9237A7BA-6DBC-404B-A348-C765BC9A7F61Q50036572-FA75E4BE-6252-4B3B-8E14-DF7AA4119538Q53080980-6337B28A-EC64-4701-9A00-49CBC32E1D9FQ57137026-02B55937-F71C-4E2A-B33D-D28DBC546D2AQ58630430-242452C5-F20D-4C03-9873-8CFABB61F815
P2860
In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 May 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vivo imaging of endogenous ...... -dihydrotetrabenazine and PET.
@en
In vivo imaging of endogenous ...... -dihydrotetrabenazine and PET.
@nl
type
label
In vivo imaging of endogenous ...... -dihydrotetrabenazine and PET.
@en
In vivo imaging of endogenous ...... -dihydrotetrabenazine and PET.
@nl
prefLabel
In vivo imaging of endogenous ...... -dihydrotetrabenazine and PET.
@en
In vivo imaging of endogenous ...... -dihydrotetrabenazine and PET.
@nl
P2093
P2860
P1476
In vivo imaging of endogenous ...... -dihydrotetrabenazine and PET.
@en
P2093
Daniel M Skovronsky
Gary W Cline
Judith L Treadway
Kevan C Herold
Krista Fowles
Marc D Normandin
Richard E Carson
Roberto A Calle
Sarita Naik
Shu-Fei Lin
P2860
P304
P356
10.2967/JNUMED.111.100545
P407
P577
2012-05-09T00:00:00Z